HTML Microdata document

This HTML5 document contains 39 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB05143/identifier/chemspider/
n10	http://bio2rdf.org/drugbank:
adms	http://www.w3.org/ns/adms#
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n8	http://linked.opendata.cz/resource/drugbank/drug/DB05143/identifier/bindingdb/
owl	http://www.w3.org/2002/07/owl#
n11	http://linked.opendata.cz/resource/drugbank/drug/DB05143/identifier/pubchem-compound/
n3	http://linked.opendata.cz/ontology/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n7	http://linked.opendata.cz/resource/drugbank/drug/DB05143/identifier/drugbank/

Statements

Subject Item: n2:DB05143
rdf:type: n3:Drug
n3:description: OXI4503 is investigated in clinical trials for treating cancer/tumors. OXI4503 is a solid. OXI4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. OXI4503 (combretastatin A1 di-phosphate / CA1P) is a unique and highly potent, dual-mechanism vascular disrupting agent (VDA). In addition, however, preclinical data demonstrates that OXI4503 is metabolized by oxidative enzymes (e.g., tyrosinase and peroxidases), which are elevated in many solid tumors and tumor infiltrates, to an orthoquinone chemical species that has direct cytotoxic effects on tumor cells. Preclinical studies have demonstrated that OXI4503 has (i) single-agent activity against a range of xenograft tumor models; and (ii) synergistic or additive effects when incorporated in various combination regimens with chemotherapy, molecularly-targeted therapies (including tumor-angiogenesis inhibitors), and radiation therapy.
n3:generalReferences: # Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C: Alterations in vascular architecture and permeability following OXi4503 treatment. Anticancer Drugs. 2008 Jan;19(1):17-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18043126 # Hokland SL, Horsman MR: The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Int J Hyperthermia. 2007 Nov;23(7):599-606. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18038290 # Chan LS, Malcontenti-Wilson C, Muralidharan V, Christophi C: Effect of vascular targeting agent Oxi4503 on tumor cell kinetics in a mouse model of colorectal liver metastasis. Anticancer Res. 2007 Jul-Aug;27(4B):2317-23. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17695520 # Salmon HW, Siemann DW: Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res. 2006 Jul 1;12(13):4090-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16818709
n3:group: investigational
n3:indication: Investigated for use/treatment in cancer/tumors (unspecified).
owl:sameAs: n10:DB05143
dcterms:title: OXI4503
adms:identifier: n6:5293742 n7:DB05143 n8:50236033 n11:6918545
n3:mechanismOfAction: OXi4503 blocks and destroys tumor vasculature, resulting in extensive tumor cell death and necrosis. It induced the shutdown of tumor blood vessels and affected peripheral tumor regions less than central regions.
n3:IUPAC-Name: n4:271B64B1-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B64B7-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B64B6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B64B3-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B64B4-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B64B5-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B64AF-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B64B0-363D-11E5-9242-09173F13E4C5 n4:271B64AD-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B64AE-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count: n4:271B64BD-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B64BE-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B64B8-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B64B9-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B64BB-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B64BA-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B64BC-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber: 288847-35-8
n3:Bioavailability: n4:271B64C3-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B64C5-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B64C6-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B64C2-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B64C1-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B64C4-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B64B2-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B64BF-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-: n4:271B64C0-363D-11E5-9242-09173F13E4C5